Transgenically produced antithrombin III

• US 20080176786A1
• Filed: 11/14/2005
• Published: 07/24/2008
• Est. Priority Date: 02/21/1995
• Status: Active Grant

• Current Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Original Assignee: GTC Biotherapeutics, Inc.
• Inventors: Cole, Edward S., Meade, Harry M., Ditullio, Paul
• Granted Patent: US 7,928,064 B2
• Time in Patent Office: Days
• US Class Current: 514/8
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: C07K 14/8128 Antithrombin III
• CPC Class Codes: Y10S 530/832 Milk; colostrum

Abstract

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Claims

1-11. -11. (canceled)

12. A method of treating a subject having an antithrombin III (ATE) deficiency or inflammation, comprising:

administering to a patient a non-human mammal mammary gland produced recombinant antithrombin III (ATIII).